NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / COVID-19 vaccine Corbevax's samples cleared by India's apex testing laboratory
    India

    COVID-19 vaccine Corbevax's samples cleared by India's apex testing laboratory

    COVID-19 vaccine Corbevax's samples cleared by India's apex testing laboratory
    Written by Pratyush Deep Kotoky
    Nov 06, 2021, 12:56 pm 3 min read
    COVID-19 vaccine Corbevax's samples cleared by India's apex testing laboratory
    If Corbevax gets emergency use approval in India, it would be the third indigenous vaccine to be administered in the country.

    Hyderabad-based pharmaceutical company Biological E's COVID-19 vaccine Corbevex's samples were cleared by the Central Drugs Laboratory in Kasauli on Tuesday. The move will help the company kickstart manufacturing and stockpiling its vaccine for roll-out in the country's vaccination program against COVID-19. Notably, Corbevax is India's third indigenous COVID-19 vaccine after COVAXIN and ZyCoV-D. Here are more details.

    Why does it matter?

    • If Corbevax gets emergency use approval in India, it would be the third indigenous vaccine to be administered in the country.
    • Officials maintained the vaccine is likely to get India's drug regulator's approval by November-end or December.
    • However, there won't be many receivers of the vaccine as the majority of Indians are already inoculated with existing COVID-19 vaccines administered in the country—COVAXIN or Covishield.

    Corbevax to get emergency use approval November-end, December: Official

    A senior official at the Ministry of Health and Family Welfare told CNN-News18 that the clearance report of Corbevax has been sent to the Drug Controller General of India (DGCI). "The company will soon be informed by his (DGCI) office," the official added. The vaccine is likely to get the emergency use approval by the end of November or December, the official said.

    There will be few takers of the vaccine: Official

    The official said the Corbevax would have a "narrow audience" for vaccination when it becomes available in the market. This is because 80% of Indians are already partially inoculated with either COVAXIN or Covishield, and existing protocols won't allow them to mix Corbevax as their second dose. Furthermore, millions of doses of already available vaccines have also been lined up for testing at CDL.

    Trials on children and booster jab ongoing: Report

    Meanwhile, the trials are ongoing to use Corbevax for COVID-19 vaccination on children, CNN-News18 reported. The vaccine is also being examined for its potential use as a single-dose booster jab on those inoculated with COVAXIN and Covishield.

    How does Corbevax work against COVID-19?

    Corbevax is a recombinant protein subunit vaccine, which uses a specific part—spike protein—of SARS CoV-2, the coronavirus that causes COVID-19, to trigger an immune response against COVID-19 in advance. The novel coronavirus uses spike proteins to latch onto human cells. Since Corbevax injects spike protein without the virus, the body uses the antibodies generated to fight the real virus when it attempts to infect.

    Government ordered 30 crore doses of Corbevax by December

    The central government is considering Corbevax as a high-potential vaccine and has placed an order for 30 crore doses to be supplied by December. The Centre had also made an advance payment of Rs. 1,500 crore for the same, reports claimed.

    Corbevax's manufacturing faced setback due to shortage of raw material

    Earlier in June, the Centre had announced that Biological E would start manufacturing and stockpiling Corbevax from August-December 2021. However, the production of the vaccine had reportedly faced a setback due to the unavailability of certain imported raw materials. "In September, the company managed to procure the raw material," an official told CNN-News18.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    India
    Ministry of Health and Family Welfare
    COVID-19 Vaccine
    COVID-19 Vaccination

    Latest

    Women's Premier League 2023: Tahlia McGrath smashes her fourth fifty Women's Premier League (WPL)
    WPL 2023: UPW compile 138/6 against DC; McGrath, Capsey shine Women's Premier League (WPL)
    Google releases Bard, its rival to OpenAI's ChatGPT Google Bard
    HC slams Punjab Police for failing to arrest Amritpal Singh Haryana High Court

    India

    India witnessed significant human rights violations in 2022: US report United States of America
    Bullish on India, but Lamborghini CEO is unhappy with infrastructure Lamborghini
    Can't confirm: US on providing India intelligence about China's incursion United States of America
    'Absolutely unacceptable': US condemns attack on Indian consulate by pro-Khalistanis United States of America

    Ministry of Health and Family Welfare

    H3N2: Experts advise caution as deaths and ICU admissions rise COVID-19
    Marion Biotech, linked to Uzbekistan kids' death, halts production   Mansukh Mandaviya
    Uzbekistan links death of 18 kids to Noida-made cough syrup Noida
    COVID-19 test mandatory for arrivals from China, 4 other countries COVID-19

    COVID-19 Vaccine

    IIT Delhi develops new COVID-19 vaccine using immune cells COVID-19
    India's 1st nasal COVID-19 vaccine by Bharat Biotech launched COVID-19
    Bharat Biotech's iNCOVACC: Here's how much COVID-19 nasal vaccine costs Bharat Biotech
    COVID-19: Mock drills across India to test preparedness; more updates COVID-19

    COVID-19 Vaccination

    Gurugram: Woman confined herself, son for 3 years fearing COVID-19 Gurugram
    Centre refutes reports on side-effects of COVID-19 vaccines Union Health Ministry
    Chinese residents hesitant of COVID-19 vaccine as cases rise: Reports China
    China may witness over 1 million COVID-19 deaths in 2023 China

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023